Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis

Vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) remain major health problems for women. VT-1161, a novel fungal CYP51 inhibitor which has potent antifungal activity against fluconazole-sensitive Candida albicans, retained its in vitro potency (MIC(50) of ≤0.015 and MIC(90) of 0.12 μg/ml) aga...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Sobel, J. D., Lilly, E. A., Fidel, P. L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2015
Schlagworte:
Experimental Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538529/
https://ncbi.nlm.nih.gov/pubmed/26124165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00185-15
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge